Female Infertility – Pipeline Review, H2 2012
出 版 商：Global Markets Direct
出版日期：2012/08/31
頁 數：151頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Female Infertility – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Female Infertility - Pipeline Review, H2 2012', provides an overview of the Female Infertility therapeutic pipeline. This report provides information on the therapeutic development for Female Infertility, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Female Infertility. 'Female Infertility - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Female Infertility.
- A review of the Female Infertility products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Female Infertility pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Female Infertility.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Female Infertility pipeline depth and focus of Female Infertility therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Summary
Global Markets Direct’s, 'Female Infertility - Pipeline Review, H2 2012', provides an overview of the Female Infertility therapeutic pipeline. This report provides information on the therapeutic development for Female Infertility, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Female Infertility. 'Female Infertility - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Female Infertility.
- A review of the Female Infertility products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Female Infertility pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Female Infertility.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Female Infertility pipeline depth and focus of Female Infertility therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Female Infertility Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Female Infertility 9
Female Infertility Therapeutics under Development by Companies 11
Female Infertility Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 18
Comparative Analysis 18
Mid Clinical Stage Products 19
Comparative Analysis 19
Early Clinical Stage Products 20
Comparative Analysis 20
Discovery and Pre-Clinical Stage Products 21
Comparative Analysis 21
Female Infertility Therapeutics – Products under Development by Companies 22
Female Infertility Therapeutics – Products under Investigation by Universities/Institutes 25
Companies Involved in Female Infertility Therapeutics Development 27
Abbott Laboratories 27
Vyteris, Inc. 28
Watson Pharmaceuticals, Inc. 29
Merck & Co., Inc. 30
Euroscreen S.A. 31
Takeda Pharmaceutical Company Limited 32
Mochida Pharmaceutical Co., Ltd. 33
Astellas Pharma Inc. 34
Dong-A Pharmaceutical Co., Ltd. 35
Kissei Pharmaceutical Co., Ltd. 36
Teva Pharmaceutical Industries Limited 37
Zydus Cadila Healthcare Limited 38
Pantec Biosolutions AG 39
Access Pharmaceuticals, Inc. 40
Addex Pharmaceuticals 41
ValiRx Plc 42
AEterna Zentaris Inc. 43
Soligenix, Inc. 44
Camurus AB 45
Glycotope GmbH 46
Peptron, Inc. 47
Meditrina Pharmaceuticals, Inc. 48
PregLem SA 49
EndoCeutics, Inc. 50
Trophogen, Inc. 51
Isifer AB 52
Clarassance, Inc. 53
Female Infertility – Therapeutics Assessment 54
Assessment by Monotherapy Products 54
Assessment by Combination Products 55
Assessment by Route of Administration 56
Assessment by Molecule Type 58
Drug Profiles 61
AEZS-115 - Drug Profile 61
TAK-385 - Drug Profile 62
Elagolix - Drug Profile 63
ADX68692 - Drug Profile 65
LPM Leuprolide - Drug Profile 66
Fertility Hormone - Drug Profile 68
SR Leuprolide - Drug Profile 69
PGL1001 - Drug Profile 70
PGL2001 - Drug Profile 71
ESN-364 - Drug Profile 72
VAL 201 - Drug Profile 73
Elonva - Drug Profile 74
DA-3803 - Drug Profile 76
Metformin - Drug Profile 77
Raloxifene - Drug Profile 79
Letrozole - Drug Profile 81
Clomiphene Citrate - Drug Profile 82
Human Chorionic Gonadotropin + Clomiphene Citrate - Drug Profile 83
Leuprolide Acetate - Drug Profile 85
Microdose GnRh Agonist - Drug Profile 87
MPI-676 - Drug Profile 88
Progesterone - Drug Profile 90
Synthetic Gonadotropin Releasing Hormone - Drug Profile 92
XM17 - Drug Profile 93
D-chiro-inositol - Drug Profile 94
Simvastatin - Drug Profile 95
Goserelin Acetate - Drug Profile 96
KLH-2109 - Drug Profile 97
Femara - Drug Profile 98
Neupogen - Drug Profile 99
Recombinant Follicle Stimulating Hormone - Drug Profile 101
Prod-6 - Drug Profile 102
Medroxyprogesterone - Drug Profile 103
Oral Infertility Drugs - Drug Profile 104
Afolia - Drug Profile 105
Afolia - Drug Profile 106
ASP1707 - Drug Profile 107
Neupogen - Drug Profile 108
Endole - Drug Profile 109
HM12160B - Drug Profile 110
FSH-GEX - Drug Profile 111
MJR-35 - Drug Profile 113
IVF001 - Drug Profile 114
IVF002 - Drug Profile 116
PGL5001 - Drug Profile 117
Prod 5 - Drug Profile 118
CG532 - Drug Profile 119
Prod 7 - Drug Profile 120
Inhibitor of 17 Beta-Hydroxysteroid Dehydrogenase Type 1 - Drug Profile 121
Femivia - Drug Profile 122
Acolbifene - Drug Profile 123
LH Analog - Drug Profile 124
Female Infertility Therapeutics – Drug Profile Updates 125
Female Infertility Therapeutics – Discontinued Products 131
Female Infertility Therapeutics - Dormant Products 133
Female Infertility – Product Development Milestones 138
Featured News & Press Releases 138
Appendix 146
Methodology 146
Coverage 146
Secondary Research 146
Primary Research 146
Expert Panel Validation 146
Contact Us 147
Disclaimer 147
List of Tables
Number of Products Under Development for Female Infertility, H2 2012 13
Products under Development for Female Infertility – Comparative Analysis, H2 2012 14
Number of Products under Development by Companies, H2 2012 16
Number of Products under Development by Companies, H2 2012 (Contd..1) 17
Number of Products under Development by Companies, H2 2012 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H2 2012 20
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 21
Comparative Analysis by Late Stage Development, H2 2012 22
Comparative Analysis by Mid Clinical Stage Development, H2 2012 23
Comparative Analysis by Early Clinical Stage Development, H2 2012 24
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 25
Products under Development by Companies, H2 2012 26
Products under Development by Companies, H2 2012 (Contd..1) 27
Products under Development by Companies, H2 2012 (Contd..2) 28
Products under Investigation by Universities/Institutes, H2 2012 29
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 30
Abbott Laboratories, H2 2012 31
Vyteris, Inc., H2 2012 32
Watson Pharmaceuticals, Inc., H2 2012 33
Merck & Co., Inc., H2 2012 34
Euroscreen S.A., H2 2012 35
Takeda Pharmaceutical Company Limited, H2 2012 36
Mochida Pharmaceutical Co., Ltd., H2 2012 37
Astellas Pharma Inc., H2 2012 38
Dong-A Pharmaceutical Co., Ltd., H2 2012 39
Kissei Pharmaceutical Co., Ltd., H2 2012 40
Teva Pharmaceutical Industries Limited, H2 2012 41
Zydus Cadila Healthcare Limited, H2 2012 42
Pantec Biosolutions AG, H2 2012 43
Access Pharmaceuticals, Inc., H2 2012 44
Addex Pharmaceuticals, H2 2012 45
ValiRx Plc, H2 2012 46
AEterna Zentaris Inc., H2 2012 47
Soligenix, Inc., H2 2012 48
Camurus AB, H2 2012 49
Glycotope GmbH, H2 2012 50
Peptron, Inc., H2 2012 51
Meditrina Pharmaceuticals, Inc., H2 2012 52
PregLem SA, H2 2012 53
EndoCeutics, Inc., H2 2012 54
Trophogen, Inc., H2 2012 55
Isifer AB, H2 2012 56
Clarassance, Inc., H2 2012 57
Assessment by Monotherapy Products, H2 2012 58
Assessment by Combination Products, H2 2012 59
Assessment by Stage and Route of Administration, H2 2012 61
Assessment by Stage and Molecule Type, H2 2012 64
Female Infertility Therapeutics – Drug Profile Updates 129
Female Infertility Therapeutics – Discontinued Products 135
Female Infertility Therapeutics – Discontinued Products (Contd..1) 136
Female Infertility Therapeutics – Dormant Products 137
Female Infertility Therapeutics – Dormant Products (Contd..1) 138
Female Infertility Therapeutics – Dormant Products (Contd..2) 139
Female Infertility Therapeutics – Dormant Products (Contd..3) 140
Female Infertility Therapeutics – Dormant Products (Contd..4) 141
List of Figures
Number of Products under Development for Female Infertility, H2 2012 13
Products under Development for Female Infertility – Comparative Analysis, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 19
Late Stage Products, H2 2012 22
Mid Clinical Stage Products, H2 2012 23
Early Clinical Stage Products, H2 2012 24
Discovery and Pre-Clinical Stage Products, H2 2012 25
Assessment by Monotherapy Products, H2 2012 58
Assessment by Combination Products, H2 2012 59
Assessment by Route of Administration, H2 2012 60
Assessment by Stage and Route of Administration, H2 2012 61
Assessment by Molecule Type, H2 2012 62
Assessment by Stage and Molecule Type, H2 2012 63
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Female Infertility Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Female Infertility 9
Female Infertility Therapeutics under Development by Companies 11
Female Infertility Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 18
Comparative Analysis 18
Mid Clinical Stage Products 19
Comparative Analysis 19
Early Clinical Stage Products 20
Comparative Analysis 20
Discovery and Pre-Clinical Stage Products 21
Comparative Analysis 21
Female Infertility Therapeutics – Products under Development by Companies 22
Female Infertility Therapeutics – Products under Investigation by Universities/Institutes 25
Companies Involved in Female Infertility Therapeutics Development 27
Abbott Laboratories 27
Vyteris, Inc. 28
Watson Pharmaceuticals, Inc. 29
Merck & Co., Inc. 30
Euroscreen S.A. 31
Takeda Pharmaceutical Company Limited 32
Mochida Pharmaceutical Co., Ltd. 33
Astellas Pharma Inc. 34
Dong-A Pharmaceutical Co., Ltd. 35
Kissei Pharmaceutical Co., Ltd. 36
Teva Pharmaceutical Industries Limited 37
Zydus Cadila Healthcare Limited 38
Pantec Biosolutions AG 39
Access Pharmaceuticals, Inc. 40
Addex Pharmaceuticals 41
ValiRx Plc 42
AEterna Zentaris Inc. 43
Soligenix, Inc. 44
Camurus AB 45
Glycotope GmbH 46
Peptron, Inc. 47
Meditrina Pharmaceuticals, Inc. 48
PregLem SA 49
EndoCeutics, Inc. 50
Trophogen, Inc. 51
Isifer AB 52
Clarassance, Inc. 53
Female Infertility – Therapeutics Assessment 54
Assessment by Monotherapy Products 54
Assessment by Combination Products 55
Assessment by Route of Administration 56
Assessment by Molecule Type 58
Drug Profiles 61
AEZS-115 - Drug Profile 61
TAK-385 - Drug Profile 62
Elagolix - Drug Profile 63
ADX68692 - Drug Profile 65
LPM Leuprolide - Drug Profile 66
Fertility Hormone - Drug Profile 68
SR Leuprolide - Drug Profile 69
PGL1001 - Drug Profile 70
PGL2001 - Drug Profile 71
ESN-364 - Drug Profile 72
VAL 201 - Drug Profile 73
Elonva - Drug Profile 74
DA-3803 - Drug Profile 76
Metformin - Drug Profile 77
Raloxifene - Drug Profile 79
Letrozole - Drug Profile 81
Clomiphene Citrate - Drug Profile 82
Human Chorionic Gonadotropin + Clomiphene Citrate - Drug Profile 83
Leuprolide Acetate - Drug Profile 85
Microdose GnRh Agonist - Drug Profile 87
MPI-676 - Drug Profile 88
Progesterone - Drug Profile 90
Synthetic Gonadotropin Releasing Hormone - Drug Profile 92
XM17 - Drug Profile 93
D-chiro-inositol - Drug Profile 94
Simvastatin - Drug Profile 95
Goserelin Acetate - Drug Profile 96
KLH-2109 - Drug Profile 97
Femara - Drug Profile 98
Neupogen - Drug Profile 99
Recombinant Follicle Stimulating Hormone - Drug Profile 101
Prod-6 - Drug Profile 102
Medroxyprogesterone - Drug Profile 103
Oral Infertility Drugs - Drug Profile 104
Afolia - Drug Profile 105
Afolia - Drug Profile 106
ASP1707 - Drug Profile 107
Neupogen - Drug Profile 108
Endole - Drug Profile 109
HM12160B - Drug Profile 110
FSH-GEX - Drug Profile 111
MJR-35 - Drug Profile 113
IVF001 - Drug Profile 114
IVF002 - Drug Profile 116
PGL5001 - Drug Profile 117
Prod 5 - Drug Profile 118
CG532 - Drug Profile 119
Prod 7 - Drug Profile 120
Inhibitor of 17 Beta-Hydroxysteroid Dehydrogenase Type 1 - Drug Profile 121
Femivia - Drug Profile 122
Acolbifene - Drug Profile 123
LH Analog - Drug Profile 124
Female Infertility Therapeutics – Drug Profile Updates 125
Female Infertility Therapeutics – Discontinued Products 131
Female Infertility Therapeutics - Dormant Products 133
Female Infertility – Product Development Milestones 138
Featured News & Press Releases 138
Appendix 146
Methodology 146
Coverage 146
Secondary Research 146
Primary Research 146
Expert Panel Validation 146
Contact Us 147
Disclaimer 147
List of Tables
Number of Products Under Development for Female Infertility, H2 2012 13
Products under Development for Female Infertility – Comparative Analysis, H2 2012 14
Number of Products under Development by Companies, H2 2012 16
Number of Products under Development by Companies, H2 2012 (Contd..1) 17
Number of Products under Development by Companies, H2 2012 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H2 2012 20
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 21
Comparative Analysis by Late Stage Development, H2 2012 22
Comparative Analysis by Mid Clinical Stage Development, H2 2012 23
Comparative Analysis by Early Clinical Stage Development, H2 2012 24
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 25
Products under Development by Companies, H2 2012 26
Products under Development by Companies, H2 2012 (Contd..1) 27
Products under Development by Companies, H2 2012 (Contd..2) 28
Products under Investigation by Universities/Institutes, H2 2012 29
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 30
Abbott Laboratories, H2 2012 31
Vyteris, Inc., H2 2012 32
Watson Pharmaceuticals, Inc., H2 2012 33
Merck & Co., Inc., H2 2012 34
Euroscreen S.A., H2 2012 35
Takeda Pharmaceutical Company Limited, H2 2012 36
Mochida Pharmaceutical Co., Ltd., H2 2012 37
Astellas Pharma Inc., H2 2012 38
Dong-A Pharmaceutical Co., Ltd., H2 2012 39
Kissei Pharmaceutical Co., Ltd., H2 2012 40
Teva Pharmaceutical Industries Limited, H2 2012 41
Zydus Cadila Healthcare Limited, H2 2012 42
Pantec Biosolutions AG, H2 2012 43
Access Pharmaceuticals, Inc., H2 2012 44
Addex Pharmaceuticals, H2 2012 45
ValiRx Plc, H2 2012 46
AEterna Zentaris Inc., H2 2012 47
Soligenix, Inc., H2 2012 48
Camurus AB, H2 2012 49
Glycotope GmbH, H2 2012 50
Peptron, Inc., H2 2012 51
Meditrina Pharmaceuticals, Inc., H2 2012 52
PregLem SA, H2 2012 53
EndoCeutics, Inc., H2 2012 54
Trophogen, Inc., H2 2012 55
Isifer AB, H2 2012 56
Clarassance, Inc., H2 2012 57
Assessment by Monotherapy Products, H2 2012 58
Assessment by Combination Products, H2 2012 59
Assessment by Stage and Route of Administration, H2 2012 61
Assessment by Stage and Molecule Type, H2 2012 64
Female Infertility Therapeutics – Drug Profile Updates 129
Female Infertility Therapeutics – Discontinued Products 135
Female Infertility Therapeutics – Discontinued Products (Contd..1) 136
Female Infertility Therapeutics – Dormant Products 137
Female Infertility Therapeutics – Dormant Products (Contd..1) 138
Female Infertility Therapeutics – Dormant Products (Contd..2) 139
Female Infertility Therapeutics – Dormant Products (Contd..3) 140
Female Infertility Therapeutics – Dormant Products (Contd..4) 141
List of Figures
Number of Products under Development for Female Infertility, H2 2012 13
Products under Development for Female Infertility – Comparative Analysis, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 19
Late Stage Products, H2 2012 22
Mid Clinical Stage Products, H2 2012 23
Early Clinical Stage Products, H2 2012 24
Discovery and Pre-Clinical Stage Products, H2 2012 25
Assessment by Monotherapy Products, H2 2012 58
Assessment by Combination Products, H2 2012 59
Assessment by Route of Administration, H2 2012 60
Assessment by Stage and Route of Administration, H2 2012 61
Assessment by Molecule Type, H2 2012 62
Assessment by Stage and Molecule Type, H2 2012 63
